RxDoctor Payments Data

Ashley Springston

Optometrist · Huntingburg, INNPI 1326033036

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 43.3% of the total. That places this record below the midpoint for optometrist clinicians in IN, where the typical reported total is $555.

$275in general payments, 2019–2025

Across 15 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$119
  • Coopervision Inc.$58
  • AbbVie$36
  • Johnson & Johnson Vision Care, Inc.$34
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$15
  • Aerie Pharmaceuticals, Inc.$14

What the payments were for

  • Food & beverage$275100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$275 in reported general payments places this provider in the 30th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$84,500
Medicare patients
478
Services billed
1,190

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost39$21,154
Latanoprost210$1,737
Timolol Maleate105$1,100
Brimonidine Tartrate31$736
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat31$594
Dorzolamide Hcl20$360
ErythromycinErythromycin Base12$86

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$36$21,15439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Huntingburg

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →